Maravai Lifesciences Holdings (MRVI) AI Stock Analysis

• Market Cap: $783.96M
• Dividend Yield: N/A
• Average Volume (3M): 1.58M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: -22.52%
• EPS Growth: -37.00%
• Country: US
• Employees: 570
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 144,677,780
• 10 Day Avg. Volume: 1,207,157
• 30 Day Avg. Volume: 1,580,297
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.83
• Enterprise Value/Revenue: 3.02
• Enterprise Value/Gross Profit: 10.36
• Enterprise Value/Ebitda: -2.29
• 1Y Price Target: $4.67
• Price Target Upside: 52.12% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 46 Neutral
• Price Target: $3.00 ▼(-2.28% Downside)

Maravai Lifesciences Holdings is currently facing significant financial difficulties, with negative profitability and declining revenue being the most critical factors. While there are some positive technical indicators and strategic initiatives, the overall outlook remains pressured by financial instability and valuation concerns.

Positive Factors

Restructuring and Cost Reduction

The restructuring plan aims to reduce expenses significantly, which can improve profitability and financial stability over the long term.

Biologics Safety Testing Segment Growth

Growth in this segment indicates strong demand for safety testing products, supporting revenue diversification and long-term growth.

Positive Prospects in China

Expansion into China can provide new revenue streams and mitigate risks associated with the U.S. market challenges.

Negative Factors

Significant Revenue Drop

The substantial revenue decline highlights challenges in core segments, impacting financial performance and market position.

GAAP Net Loss Increase

Increased net losses indicate worsening profitability, which can strain resources and hinder future investments.

Challenges in U.S. Market

Reduced demand in the U.S. market could limit growth prospects and affect overall revenue, necessitating strategic adjustments.

Maravai Lifesciences Holdings Business Overview & Revenue Model

Company Description

Maravai Lifesciences Holdings (MRVI) is a leading provider of life sciences tools and services, focused on enabling the development of new therapies and the advancement of scientific research. The company operates primarily in three sectors: nucleic acid production, protein detection, and cell line development. Its core products include custom nucleic acids, detection reagents, and cell line development services, which are critical for applications in genomics, diagnostics, and biopharmaceutical manufacturing.

How the Company Makes Money

Maravai Lifesciences generates revenue through multiple streams, primarily by providing high-quality nucleic acid products and services to biotechnology and pharmaceutical companies, academic institutions, and contract research organizations. Key revenue streams include sales of custom oligonucleotides, RNA production, and reagents for molecular biology applications. The company also benefits from partnerships with major players in the biopharmaceutical industry, enhancing its market position and driving sales growth. Furthermore, the increasing demand for mRNA-based therapeutics and vaccines, particularly highlighted during the COVID-19 pandemic, has contributed significantly to Maravai's earnings, as its products are pivotal in the development and manufacturing of these innovative therapies.

Maravai Lifesciences Holdings Financial Statement Overview

Summary

Maravai Lifesciences Holdings is experiencing severe financial challenges, with declining revenue and profitability. The income statement shows negative margins, and the balance sheet reflects negative returns on equity. Although there are improvements in cash flow, overall cash generation remains a concern.

Income Statement

Maravai Lifesciences Holdings has experienced a significant decline in revenue and profitability over the TTM period. The gross profit margin has decreased from previous years, and the net profit margin is negative, indicating losses. Revenue growth has been negative, reflecting a challenging market environment. The EBIT and EBITDA margins are also negative, highlighting operational inefficiencies.

Balance Sheet

The company's balance sheet shows a relatively low debt-to-equity ratio in the TTM period, which is a positive sign of reduced leverage. However, the return on equity is negative, indicating that the company is not generating sufficient returns on shareholder investments. The equity ratio is stable, but the overall financial health is impacted by declining profitability.

Cash Flow

The cash flow statement reveals a significant improvement in free cash flow growth, although it remains negative. The operating cash flow to net income ratio is negative, indicating cash flow challenges. However, the free cash flow to net income ratio is positive, suggesting some ability to generate cash relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	215.85M	259.19M	288.94M	883.00M	799.24M	284.10M
Gross Profit	62.83M	108.31M	140.20M	714.04M	658.68M	204.45M
EBITDA	-284.12M	-156.92M	712.41M	609.99M	585.78M	138.27M
Net Income	-194.72M	-144.85M	-119.03M	220.21M	182.04M	76.89M
Balance Sheet
Total Assets	896.97M	1.01B	1.49B	2.28B	1.92B	1.27B
Cash, Cash Equivalents and Short-Term Investments	269.91M	322.40M	574.96M	632.14M	551.27M	236.18M
Total Debt	371.08M	376.69M	610.97M	585.26M	575.22M	590.78M
Total Liabilities	428.98M	431.04M	697.57M	1.38B	1.37B	1.12B
Stockholders Equity	265.86M	325.29M	416.75M	545.22M	315.50M	88.51M
Cash Flow
Free Cash Flow	-44.21M	-22.19M	60.67M	518.89M	353.72M	126.78M
Operating Cash Flow	-21.16M	7.46M	126.22M	535.98M	368.57M	152.19M
Investing Cash Flow	-40.26M	-24.32M	-122.31M	-267.61M	105.66M	6.07M
Financing Cash Flow	-240.57M	-235.71M	-61.09M	-187.50M	-159.05M	53.21M

Maravai Lifesciences Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.07
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRVI, the sentiment is Neutral. The current price of 3.07 is below the 20-day moving average (MA) of 3.29, above the 50-day MA of 2.89, and above the 200-day MA of 2.80, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 46.36 is Neutral, neither overbought nor oversold. The STOCH value of 13.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MRVI.

Maravai Lifesciences Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RLAY	―	$1.18B	-3.52	-46.24%	―	-76.27%	22.77%
IMTX	―	$1.26B	―	-17.34%	―	83.36%	22.27%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KURA	―	$890.54M	―	-51.11%	―	―	-1.26%
MRVI	―	$783.96M	―	-55.41%	―	-22.52%	-37.00%
GHRS	―	$865.29M	-18.90	-16.35%	―	―	-9.82%
IVA	―	$515.24M	-1.52	―	―	-12.52%	-82.84%

Maravai Lifesciences Holdings Corporate Events

Maravai Lifesciences Streamlines Board with Recent Resignations

On October 21, 2025, Maravai LifeSciences Holdings, Inc. announced the voluntary resignation of three board members—Benjamin Daverman, Jessica Hopfield, PhD, and Murali Prahalad, PhD—as part of its strategy to streamline its Board of Directors and cut administrative costs. Consequently, the board’s size was reduced from eleven to eight members, effective October 27, 2025. The resignations were not due to any disagreements with the company’s management or policies. Following these changes, R. Andrew Eckert was appointed chair of the Nominating, Governance and Risk Committee and a member of the Audit Committee, while Gregory T. Lucier joined the Nominating, Governance and Risk Committee. The company also accelerated the vesting of all unvested restricted stock unit awards for the departing directors.

The most recent analyst rating on (MRVI) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Maravai Lifesciences Holdings stock, see the MRVI Stock Forecast page.

Maravai Lifesciences’ Earnings Call: Growth Amid Challenges

The recent earnings call for Maravai Lifesciences Holdings, Inc. presented a mixed sentiment, highlighting both promising growth areas and significant financial challenges. While the company is making strides in its Biologics Safety Testing segment and exploring new strategic initiatives, it faces substantial revenue declines and increased net losses. The restructuring efforts and growth prospects in China offer some optimism, but the financial hurdles and restructuring costs remain a concern.

Maravai LifeSciences Announces Restructuring Amid Revenue Decline

Maravai LifeSciences Holdings, Inc. is a global provider of life science reagents and services, catering primarily to researchers and biotech innovators, with a focus on nucleic acid synthesis and biologics safety testing. In its latest earnings report, Maravai announced a significant organizational restructuring aimed at achieving over $50 million in annualized cost savings. The company reported a quarterly revenue of $47.4 million, marking a 31.7% decrease year-over-year, primarily due to a decline in high-volume CleanCap orders. Despite the overall revenue drop, the base business revenue excluding CleanCap saw a 5% growth, driven by strong demand for Cygnus products and services. The company also appointed new leadership, with Bernd Brust as CEO and Raj Asarpota as CFO, to spearhead innovation and financial performance improvements. Looking ahead, Maravai is focused on realigning its cost structure and expects to achieve positive adjusted EBITDA and free cash flow by the second half of 2026, as it continues to streamline operations and enhance its market position.

Maravai Lifesciences Announces Major Organizational Restructuring

On August 11, 2025, Maravai LifeSciences announced an organizational restructuring to reduce operating costs, including a workforce reduction affecting approximately 25% of its employees. This strategic initiative, committed to on August 8, 2025, is expected to incur costs between $8.0 million and $9.0 million, primarily for employee severance and benefits. Additionally, the company reported a significant decrease in revenue for the second quarter of 2025, with a 31.7% drop compared to the previous year, largely due to reduced CleanCap orders. Despite this, Maravai is implementing cost-saving measures expected to save over $50 million annually, aiming to realign its cost structure and return to profitability.

The most recent analyst rating on (MRVI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Maravai Lifesciences Holdings stock, see the MRVI Stock Forecast page.